Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03829410
Recruitment Status : Recruiting
First Posted : February 4, 2019
Last Update Posted : June 24, 2019
Sponsor:
Information provided by (Responsible Party):
Trovagene, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 25, 2021
  Estimated Study Completion Date : May 25, 2021